These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

874 related articles for article (PubMed ID: 22454420)

  • 1. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
    Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
    J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
    Schöffski P; Jones SF; Dumez H; Infante JR; Van Mieghem E; Fowst C; Gerletti P; Xu H; Jakubczak JL; English PA; Pierce KJ; Burris HA
    Eur J Cancer; 2011 Oct; 47(15):2256-64. PubMed ID: 21852114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors.
    Shimizu T; Fukuoka K; Takeda M; Iwasa T; Yoshida T; Horobin J; Keegan M; Vaickus L; Chavan A; Padval M; Nakagawa K
    Cancer Chemother Pharmacol; 2016 May; 77(5):997-1003. PubMed ID: 27025608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
    Li T; LoRusso P; Maitland ML; Ou SH; Bahceci E; Ball HA; Park JW; Yuen G; Tolcher A
    J Hematol Oncol; 2016 Mar; 9():23. PubMed ID: 26966027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
    Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
    Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
    Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
    Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
    Leong S; Moss RA; Bowles DW; Ware JA; Zhou J; Spoerke JM; Lackner MR; Shankar G; Schutzman JL; van der Noll R; Voest EE; Schellens JHM
    Oncologist; 2017 Dec; 22(12):1491-1499. PubMed ID: 28798270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.
    Jones SF; Siu LL; Bendell JC; Cleary JM; Razak AR; Infante JR; Pandya SS; Bedard PL; Pierce KJ; Houk B; Roberts WG; Shreeve SM; Shapiro GI
    Invest New Drugs; 2015 Oct; 33(5):1100-7. PubMed ID: 26334219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
    Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J
    J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.
    Spreafico A; Delord JP; De Mattos-Arruda L; Berge Y; Rodon J; Cottura E; Bedard PL; Akimov M; Lu H; Pain S; Kaag A; Siu LL; Cortes J
    Br J Cancer; 2015 Feb; 112(4):650-9. PubMed ID: 25625276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
    Leijen S; Middleton MR; Tresca P; Kraeber-Bodéré F; Dieras V; Scheulen ME; Gupta A; Lopez-Valverde V; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Schellens JH; Eberhardt WE
    Clin Cancer Res; 2012 Sep; 18(17):4794-805. PubMed ID: 22767668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic
    Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R
    Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198
    [No Abstract]   [Full Text] [Related]  

  • 14. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study.
    Peeva E; Hodge MR; Kieras E; Vazquez ML; Goteti K; Tarabar SG; Alvey CW; Banfield C
    Br J Clin Pharmacol; 2018 Aug; 84(8):1776-1788. PubMed ID: 29672897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
    Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
    J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
    Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
    Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
    Shapiro GI; Rodon J; Bedell C; Kwak EL; Baselga J; Braña I; Pandya SS; Scheffold C; Laird AD; Nguyen LT; Xu Y; Egile C; Edelman G
    Clin Cancer Res; 2014 Jan; 20(1):233-45. PubMed ID: 24166903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
    Edelman G; Rodon J; Lager J; Castell C; Jiang J; Van Allen EM; Wagle N; Lindeman NI; Sholl LM; Shapiro GI
    Oncologist; 2018 Apr; 23(4):401-e38. PubMed ID: 29593099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.
    Cervantes A; Elez E; Roda D; Ecsedy J; Macarulla T; Venkatakrishnan K; Roselló S; Andreu J; Jung J; Sanchis-Garcia JM; Piera A; Blasco I; Maños L; Pérez-Fidalgo JA; Fingert H; Baselga J; Tabernero J
    Clin Cancer Res; 2012 Sep; 18(17):4764-74. PubMed ID: 22753585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.